TG Therapeutics, Inc. $TGTX Stake Lowered by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 91,593 shares of the biopharmaceutical company’s stock after selling 1,090 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of TG Therapeutics worth $3,615,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TGTX. Balyasny Asset Management L.P. bought a new position in shares of TG Therapeutics during the 4th quarter valued at $274,000. Deutsche Bank AG raised its holdings in shares of TG Therapeutics by 40.4% during the 4th quarter. Deutsche Bank AG now owns 147,020 shares of the biopharmaceutical company’s stock valued at $4,425,000 after purchasing an additional 42,272 shares in the last quarter. Man Group plc bought a new position in shares of TG Therapeutics during the 4th quarter valued at $289,000. ProShare Advisors LLC raised its holdings in shares of TG Therapeutics by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 41,955 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 12,951 shares in the last quarter. Finally, Wexford Capital LP bought a new position in shares of TG Therapeutics during the 4th quarter valued at $421,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.64% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a report on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.25.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $32.16 on Friday. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The company has a fifty day simple moving average of $32.38 and a 200 day simple moving average of $35.63. The company has a market cap of $5.10 billion, a P/E ratio of 86.92 and a beta of 1.88. TG Therapeutics, Inc. has a 1 year low of $21.16 and a 1 year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.TG Therapeutics’s quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.